January to June 2025:
HARTMANN navigates a challenging market environment with resilience

Heidenheim, 14 August 2025. In the first half of 2025, HARTMANN held its ground in an overall challenging market environment. Organic sales growth of 1.6% led to sales revenues of EUR 1,214.0 million.

HARTMANN was affected by a generally weaker development in some sales markets, particularly in its two prescription wound care markets in Germany and France.

Adjusted EBITDA was at EUR 125.8 million, down EUR 10.1 million on the previous year. The adjusted EBITDA margin was 10.4%. The development of earnings is primarily attributable to higher upstream sales and marketing expenses in connection with the launch of new products and to increases in material costs, particularly for cellulose.

HARTMANN successfully migrated its SAP system to S/4 HANA in the second quarter.

Revenue in the Incontinence Management segment rose again – the strategically important incontinence pants made a particularly strong contribution.

In the Wound Care segment, advanced wound care with atraumatic dressings, such as Zetuvit® Plus Silicone Border, recorded growth.

The Infection Management segment developed steadily overall, but performance varied across the individual product groups. While sales in the areas of surface and hand disinfection products increased, the retail business with protective products declined.

In the first half of 2025, sales in the Complementary Group Divisions segment remained at the same level as the previous year.

HARTMANN is continuing to systematically implement its Transformation Program. It is expected to make an additional contribution to earnings of approximately EUR 50 million in the current fiscal year.

HARTMANN continues to anticipate moderate sales growth for the 2025 financial year. Due to weaker sales markets, increased tariffs and ongoing geopolitical uncertainty, HARTMANN is lowering its adjusted EBITDA forecast from between EUR 260 million and EUR 300 million to between EUR 250 million and EUR 290 million.

Further information on the HARTMANN financial position can be found at https://corporate.hartmann.info/de-de/investor-relations.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.